Metrics as of 10/13/2026, 06:50 PM (Berlin time), refresh in progress.
INmune Bio Stock
INmune Bio, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David J. Moss
- Employees
- 21
- Market cap
- $45 M
- IPO
- 04/02/2019
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a…
INmune Bio stock: price history
1D
-5.6%
1W
-10.2%
1M
-24.3%
6M
+33.3%
YTD
+7.7%
1Y
-8.2%
2Y
-67.3%
5Y
-90.3%
10Y
–
Next earnings date
Next earnings date
29/10/2026 (in 12 days)
Volatility around earnings
~8% weaker price swings than usual
Ask the agents about INmune Bio
Analyst assessment of INmune Bio
PRICE TARGET LOW
US$22.00
CONSENSUS
US$22.00
MEDIAN
US$22.00
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
6
BUY
2
HOLD
1
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 11/03/2026
INmune Bio stock metrics
P/E
-2.43
P/B
2.2
EV/EBITDA
-1.52
RETURN ON EQUITY
-6.3%
NET MARGIN
0.0%
DEBT/EQUITY
0.07
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.2%
FLOAT SHARES
22,131,696
AVG. DAILY VOLUME (30D)
308,693
Insider transactions (SEC)
Moss David J
Lowdell Mark William
Juda Scott
Institutional holders
Comparable stocks
Frequently asked questions about INmune Bio stock
What does INmune Bio do?
INmune Bio, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David J. Moss, the company employs around 21 people.
The IPO was on 04/02/2019; the stock trades on NASDAQ under the ticker INMB.
What do analysts say about INmune Bio stock?
9 analysts rate the stock, the consensus is Buy (as of 11/03/2026).
The average price target is US$22.00, ranging from US$22.00 to US$22.00, with a median of US$22.00.
This is an external assessment, not a statement by Market Jury.
When does INmune Bio report next?
The next earnings date is 29/10/2026.
Around past earnings, price swings were roughly -8% stronger than usual.
Does INmune Bio pay a dividend?
No, INmune Bio currently does not pay a dividend.
Which stocks are comparable to INmune Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get INmune Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess INmune Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.